• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

IHC Algorithm Enriches Equivocal HER2 Breast Cancers but Requires Confirmatory Testing

by
November 12, 2026
in Cancer, Health
Reading Time: 3 mins read
0
IHC Algorithm Enriches Equivocal HER2 Breast Cancers but Requires Confirmatory Testing

IHC Algorithm Enriches Equivocal HER2 Breast Cancers but Requires Confirmatory Testing

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In current pathological workflows, immunohistochemistry serves as the primary screening tool; however, tumors demonstrating an equivocal 2+ staining pattern invariably necessitate secondary reflex testing via in situ hybridization.

To investigate whether automated image analysis could help resolve these ambiguous clinical classifications, an investigative team evaluated the uPath HER2 (4B5) algorithm across two distinct clinical patient series. The researchers examined cases of invasive breast cancer that had been assigned an equivocal HER2 2+ score by human pathologists, subsequently re-scoring the tissue sections using the digital tool while remaining blinded to the underlying in situ hybridization reference standards. The proof-of-concept investigation aimed to determine whether artificial intelligence assistance could reliably separate true gene amplification from non-amplified status within this challenging diagnostic category.

The study protocol evaluated two cohorts structured to assess algorithmic performance under both controlled and real-world conditions. The first group consisted of a retrospective discovery cohort comprising 100 enriched cases balanced evenly between 50 in situ hybridization-amplified and 50 non-amplified specimens. The second group represented a routine-practice validation cohort containing 47 consecutive cases designed to reflect the natural prevalence of HER2 amplification encountered in routine diagnostic pathology. In structuring the analysis according to STARD and CLAIM reporting guidelines, the authors established complete confusion matrices and exact Clopper–Pearson 95% confidence intervals.

For the primary analytical framework, the investigators established an algorithmic score of uPath HER2 3+ as the positive threshold, classifying outputs of 1+ and 2+ as non-positive. Overall quantitative measurements revealed that algorithmic scoring outputs were significantly higher in confirmed in situ hybridization-amplified cases than in non-amplified counterparts, demonstrating a statistically significant divergence with a p-value of less than 0.0001 across the examined series.

Within the retrospective discovery cohort of 100 samples, the automated system re-classified 45 cases as 3+, of which 35 were confirmed to be amplified by in situ hybridization while 10 were non-amplified. This distribution resulted in a sensitivity of 70.0 percent and a specificity of 80.0 percent under the primary analytical threshold. These preliminary metrics indicated that the algorithm concentrated true gene-amplified specimens, although a notable proportion of amplified tumors failed to meet the positive cut-off, and several non-amplified cases were re-scored positively.

When the computational tool was deployed on the consecutive validation cohort representing regular clinical prevalence, its operational profile shifted noticeably. Among the 47 consecutive routine-practice specimens, the uPath platform re-scored only 4 cases, or 8.5 percent of the cohort, as 3+. Confirmatory testing showed that two of these four cases were amplified and two were non-amplified. Consequently, the primary analysis within the validation set yielded an overall sensitivity of 25.0 percent paired with an elevated specificity of 94.9 percent.

The researchers also carried out a secondary exploratory analysis that eliminated equivocal algorithm outputs by completely excluding HER2 2+ calls. When restricted to non-equivocal outcomes with 2+ cases excluded, the secondary exploratory analysis reached 100 percent sensitivity but only 9 percent specificity.

The authors concluded that while an off-the-shelf immunohistochemistry algorithm demonstrably enriches for HER2 gene amplification among equivocal 2+ breast cancer cases, its current diagnostic reliability remains insufficient to replace or eliminate mandatory confirmatory testing via in situ hybridization. These initial proof-of-concept findings highlight the prospective utility of pairing pathologist assessments with purpose-trained artificial intelligence tools, while establishing that extensive prospective and multicenter validation remains mandatory before any implementation into live clinical workflows can be considered.

Subject of Research: Diagnostic performance of an automated immunohistochemistry algorithm in equivocal HER2 breast cancer

Article Title: AI-assisted immunohistochemistry algorithm for enriching HER2-amplified cases among equivocal (2+) breast cancers: a two-cohort proof-of-concept study

Article References: Maniewski, M., Borowczak, J., Durślewicz, J., Andrusewicz, H., Dzierżawski, J., Starzyński, J., Chudzińska, P., Kowalewski, A., & Szylberg, Ł. (2026). AI-assisted immunohistochemistry algorithm for enriching HER2-amplified cases among equivocal (2+) breast cancers: a two-cohort proof-of-concept study. BMC Cancer. https://doi.org/10.1186/s12885-026-17198-2

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17198-2

Keywords: breast cancer, HER2, immunohistochemistry, in situ hybridization, uPath HER2, pathology, equivocal HER2, artificial intelligence, diagnostic performance, sensitivity, specificity, tumor testing, proof-of-concept study, computational pathology, biomarker testing, clinical validation

News Source: Nathaniel Bowman. (November 12, 2026). IHC Algorithm Enriches Equivocal HER2 Breast Cancers but Requires Confirmatory Testing. Scienmag.

Tags: Artificial Intelligencebiomarker testingBreast Cancerclinical validationcomputational pathologyDiagnostic Performanceequivocal HER2HER2Immunohistochemistryin situ hybridizationpathologyproof-of-concept studysensitivityspecificitytumor testinguPath HER2
Share12Tweet7Share2ShareShareShare1

Related Posts

Video-EEG with Polygraphy Identifies Cyanotic Breath-Holding Spell in Infant Case

Video-EEG with Polygraphy Identifies Cyanotic Breath-Holding Spell in Infant Case

November 17, 2026
Longitudinal Studies Reveal Early Executive Function Divergence Across Intellectual and Developmental Disabilities

Longitudinal Studies Reveal Early Executive Function Divergence Across Intellectual and Developmental Disabilities

November 17, 2026

Optimizing Antiemetic Therapy to Improve Supportive Care in Cancer Patients

November 17, 2026

Education and Regional Targeting Drive Optimal Antenatal Care Completion in Uganda

November 17, 2026

POPULAR NEWS

  • Sesbania Hay Replacement Modifies Lamb Muscle Lipids and Meat Flavor Precursors

    Sesbania Hay Replacement Modifies Lamb Muscle Lipids and Meat Flavor Precursors

    29 shares
    Share 12 Tweet 7
  • Human Guided Knowledge Fusion Enhances Industrial Fault Diagnosis Graphs and Retrieval

    29 shares
    Share 12 Tweet 7
  • Geostatistical Kriging Maps Regional Ionospheric Storm Anomalies Across Türkiye

    29 shares
    Share 12 Tweet 7
  • Pediatric Mononucleosis Study Finds Exploratory Links Between Viral Load and Laboratory Measures

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Video-EEG with Polygraphy Identifies Cyanotic Breath-Holding Spell in Infant Case

Longitudinal Studies Reveal Early Executive Function Divergence Across Intellectual and Developmental Disabilities

Optimizing Antiemetic Therapy to Improve Supportive Care in Cancer Patients

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.